The findings, published Nov. 3 in the Journal of the American Medical Association, reflect that although resistance fell from 2011 to 2013, it began to rise again last year. Cefixime is generally not the first line of treatment for the STD, and the CDC notes there doesn’t seem to be any decrease in effectiveness of the primary drug used to treat gonorrhea.
“It is essential to continue monitoring antimicrobial susceptibility and track patterns of resistance among the antibiotics currently used to treat gonorrhea,” Robert Kirkcaldy, MD, an epidemiologist in the CDC’s division of STD prevention and lead study author, said in a statement. “Recent increases in cefixime resistance show our work is far from over.”
The results were taken from a review of more than 51,000 samples across 34 U.S. cities.
More articles on infection control:
Up to 4,800 patients potentially exposed to hepatitis C at Utah hospital
Medication errors at Butler Memorial prompt reform
CDC scientists discover cancer case that developed from parasitic tapeworm
